Inflammation's Impact on Heart Disease and Diabetes

Launched by UNIVERSITY OF AARHUS · Dec 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how inflammation affects heart disease and diabetes, particularly in people with obesity and metabolic syndrome. Researchers want to understand if certain treatments can help reduce inflammation related to these conditions. The study involves two groups: healthy volunteers and severely obese patients who are preparing for weight-loss surgery. By comparing these groups, the researchers hope to learn how weight loss might change the body's inflammatory response and what factors might influence how individuals respond to treatment.

To participate, you need to be over 18 years old and have a specific body mass index (BMI) that fits in either the healthy or obese category. Participants will go through some initial tests to check their health, provide samples during surgery for further study, and attend follow-up visits to see how their condition changes over time. It's important to note that certain health issues, like active cancer or significant gastrointestinal problems, may exclude someone from participating. If you’re interested and meet the criteria, this study could provide valuable insights into managing inflammation and its effects on heart disease and diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals willing and able to give appropriate oral and written informed consent
• • Men and women over 18 years of age.
• • Correct body mass index (BMI) (Lean controls: 18.5-24.9 kg/m2. Obese gastric bypass patients: 35-50 kg/m2)
• Exclusion Criteria:
• • The individual does not follow instructions given in the research study.
• • Pregnancy.
• • Significant gastrointestinal problems.
• • Use of tobacco.
• • The individual consumed alcohol within two days prior to the study visit
• • Active cancer within 5 years.
• • Use of dietary supplements that impact the inflammatory resolution process (e.g., fish oils), and the person is not willing to discontinue the use of the supplements 1 week prior to the visits.
• • Underlying cardiometabolic disease, or medication related to such disease (e.g., blood pressure medication, insulin to treat diabetes, etc.).
• • Underlying inflammatory disease, or medication related to such disease.
• • The individual states that they have increased bleeding tendency or are using anti-coagulant (blood-thinning) medication.
• • For obese patients only: The individual has lost more than 8% of his/her body weight since their clinical referral for surgery or has lost more than 3% of his/her body weight in the 4 months leading up to surgery.